Bart E.C.G. de Goeij

1.0k total citations
10 papers, 788 citations indexed

About

Bart E.C.G. de Goeij is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Bart E.C.G. de Goeij has authored 10 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 3 papers in Immunology. Recurrent topics in Bart E.C.G. de Goeij's work include Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (5 papers) and Toxin Mechanisms and Immunotoxins (2 papers). Bart E.C.G. de Goeij is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (5 papers) and Toxin Mechanisms and Immunotoxins (2 papers). Bart E.C.G. de Goeij collaborates with scholars based in Netherlands, United States and Switzerland. Bart E.C.G. de Goeij's co-authors include Paul W.H.I. Parren, David Satijn, Sandra Verploegen, Esther C.W. Breij, Patrick H.C. van Berkel, Wim K. Bleeker, Richard Wubbolts, David Miao, Kristin Strumane and Jan G. J. van de Winkel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Bart E.C.G. de Goeij

10 papers receiving 758 citations

Peers

Bart E.C.G. de Goeij
Julie A. McEarchern United States
David Kan United States
Francesca Zammarchi United Kingdom
Gregory E. Jones United States
Kimberly H. Harrington United States
Abraham C.F. Leung United States
Timothy J. O rsquo Brien United States
Debora Pezzuolo Italy
Ivan Inigo United States
Daniëlle C.H. Jacobs Netherlands
Julie A. McEarchern United States
Bart E.C.G. de Goeij
Citations per year, relative to Bart E.C.G. de Goeij Bart E.C.G. de Goeij (= 1×) peers Julie A. McEarchern

Countries citing papers authored by Bart E.C.G. de Goeij

Since Specialization
Citations

This map shows the geographic impact of Bart E.C.G. de Goeij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart E.C.G. de Goeij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart E.C.G. de Goeij more than expected).

Fields of papers citing papers by Bart E.C.G. de Goeij

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart E.C.G. de Goeij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart E.C.G. de Goeij. The network helps show where Bart E.C.G. de Goeij may publish in the future.

Co-authorship network of co-authors of Bart E.C.G. de Goeij

This figure shows the co-authorship network connecting the top 25 collaborators of Bart E.C.G. de Goeij. A scholar is included among the top collaborators of Bart E.C.G. de Goeij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart E.C.G. de Goeij. Bart E.C.G. de Goeij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Hiemstra, Ida H., Kim C. M. Santegoets, Maarten L. Janmaat, et al.. (2023). Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine. 93. 104663–104663. 18 indexed citations
2.
Oostindie, Simone C., Mir Farshid Alemdehy, Maarten L. Janmaat, et al.. (2022). Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies. Blood. 140(Supplement 1). 3153–3154. 6 indexed citations
3.
Goeij, Bart E.C.G. de, Tom Vink, Esther C.W. Breij, et al.. (2016). Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63. Molecular Cancer Therapeutics. 15(11). 2688–2697. 101 indexed citations
4.
Goeij, Bart E.C.G. de, David Satijn, Richard Wubbolts, et al.. (2015). High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 14(5). 1130–1140. 78 indexed citations
5.
6.
Breij, Esther C.W., Bart E.C.G. de Goeij, Sandra Verploegen, et al.. (2013). An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. Cancer Research. 74(4). 1214–1226. 166 indexed citations
7.
Breij, Esther C.W., David Satijn, Sandra Verploegen, et al.. (2013). Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.. Journal of Clinical Oncology. 31(15_suppl). 3066–3066. 2 indexed citations
8.
Labrijn, Aran F., Joyce Meesters, Bart E.C.G. de Goeij, et al.. (2013). Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences. 110(13). 5145–5150. 251 indexed citations
9.
Kellner, Christian, Wim K. Bleeker, Jeroen J. Lammerts van Bueren, et al.. (2011). Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development. Journal of Immunological Methods. 371(1-2). 122–133. 14 indexed citations
10.
Smit, Laura A., René Spijker, Bart E.C.G. de Goeij, et al.. (2006). Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 109(4). 1660–1668. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie A. McEarchern Breakdown of academic impact, for papers by David Kan Breakdown of academic impact, for papers by Francesca Zammarchi Breakdown of academic impact, for papers by Gregory E. Jones Breakdown of academic impact, for papers by Kimberly H. Harrington Breakdown of academic impact, for papers by Abraham C.F. Leung Breakdown of academic impact, for papers by Timothy J. O rsquo Brien Breakdown of academic impact, for papers by Debora Pezzuolo Breakdown of academic impact, for papers by Ivan Inigo Breakdown of academic impact, for papers by Daniëlle C.H. Jacobs
Rankless by CCL
2026